< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

93 clusters · 431 sources · 78 days · First seen 3 months ago · Last updated 1 day ago

Categories: HEALTH · BUSINESS

Novo Nordisk obesity portfolio: EU approval, legal fight

Entities: Novo Nordisk · Semaglutide · GLP-1 receptor agonists · Ozempic · Wegovy

Overview

Novo Nordisk’s obesity portfolio keeps expanding. The European Commission confirmed marketing authorisation for the once‑daily 25 mg oral semaglutide (Wegovy) tablet, the first oral GLP‑1 approved for weight management in the EU. Based on the OASIS 4 trial, the pill produced an average 17 % body‑weight loss after 64 weeks, with one‑third of patients losing about 22 %, and it also demonstrated a 20 % reduction in major cardiovascular events.

In the United States, the oral Wegovy tablet captured strong market share, exceeding three million prescriptions since its January launch and holding roughly 89 % of the oral GLP‑1 market. It is covered under the Medicare “GLP‑1 Bridge” programme, which lets eligible seniors obtain Wegovy, Lilly’s Zepbound and the oral GLP‑1 Foundayo for a fixed $50 monthly copay. The temporary programme expires on 31 December 2027; without a permanent legislative solution, up to 3.8 million beneficiaries could lose access to treatments that cost over $1,000 a month.

Novo Nordisk escalated its legal battle with Eli Lilly, filing a temporary restraining order to halt Lilly’s advertising that it says misrepresents weight‑loss outcomes. Analysts have begun coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the expanding obesity market, the oral Wegovy launch, and a pipeline that includes higher‑dose Wegovy, CagriSema and Zenagamtide, while noting competition, pricing pressure and an upcoming patent cliff.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 4 SOURCES] GLP-1 receptor agonists are used to treat type 2 diabetes, obesity, cardiovascular disease and to promote weight loss. (e412e258-0578-4556-bd42-95505e995ce7, f242d3d5-4cbf-45f1-a37f-168feee7fa87, b1780bc7-3b20-4166-b656-9ebbd15393fc, 9431a1)
[○ 1 SOURCE] The Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge Program on July 1, 2024, offering a flat $50 monthly copayment for eligible beneficiaries. (9431a1c6-4dc1-4810-b945-64370e51ba03)
[○ 1 SOURCE] The Bridge Program covers the medications Foundayo, Wegovy and Zepbound (KwikPen). (9431a1c6-4dc1-4810-b945-64370e51ba03)
[○ 1 SOURCE] Eligibility requires specific BMI thresholds and health conditions and excludes people with type 2 diabetes, moderate‑to‑severe sleep apnea, or fatty liver disease. (9431a1c6-4dc1-4810-b945-64370e51ba03)
[○ 1 SOURCE] Regulators have warned that GLP-1 drugs can cause severe ocular side effects, including potential permanent vision loss. (f242d3d5-4cbf-45f1-a37f-168feee7fa87)
[○ 1 SOURCE] GLP-1 receptor agonists may reduce psoriasis severity, achieving 40%‑80% reductions in PASI scores in studies. (b1780bc7-3b20-4166-b656-9ebbd15393fc)
[○ 1 SOURCE] Semaglutide and liraglutide have been shown to lower inflammatory markers such as C‑reactive protein and interleukin‑6. (b1780bc7-3b20-4166-b656-9ebbd15393fc)
[○ 1 SOURCE] GLP‑1 drugs increase insulin secretion, reduce glucagon release, and slow gastric emptying. (e412e258-0578-4556-bd42-95505e995ce7)

Timeline

1 day ago

[HEALTH] 8 sources
US Medicare Launches GLP-1 Bridge Program to Cut Drug Costs
GLP‑1 drugs aid diabetes, obesity and may improve psoriasis but carry eye‑risk warnings. CMS launched a Medicare Bridge Program on July 1, offering selected GLP‑1 meds for $50/month to eligible users through  7
2 days ago

[BUSINESS] 8 sources
Novo Nordisk Seeks Injunction Against Eli Lilly's GLP-1 Advertising Amid Stock Buy Rating
Novo Nordisk filed a US injunction to block Eli Lilly's GLP‑1 ads over alleged misleading claims, while analysts initiated a BUY rating with a $68 target, citing growth in obesity treatments and pipeline assets
2 days ago

[HEALTH] 2 sources
EU Commission approves Novo Nordisk's oral weight‑loss pill
The EU Commission approved Novo Nordisk's 25 mg oral semaglutide pill for obesity and overweight, citing trial data showing 17 % average weight loss and a 20 % cut in major cardiovascular events.
3 days ago

[HEALTH] 3 sources
Medicare GLP-1 Bridge Program Set to End 2027, Threatening Access for Seniors
The Medicare GLP-1 Bridge program, offering seniors $50 copays for weight‑loss drugs, ends Dec 2027, leaving millions at risk of losing affordable access amid broader insurer cutbacks and supply shortages.
6 days ago

[BUSINESS] 5 sources
Novo Nordisk Sues Eli Lilly Over GLP‑1 Dosage Advertising Dispute
Novo Nordisk sued Eli Lilly in US federal court, claiming the rival’s GLP‑1 drug ads mislead about dosage differences and seeking ad removal and damages.
6 days ago

[BUSINESS] 4 sources
Novo Nordisk's oral GLP‑1 weight‑loss pill gets EU approval amid strict European ad rules
EU regulators approved Novo Nordisk's first oral semaglutide weight‑loss pill, while strict European ad rules contrast with the US's permissive advertising environment.
7 days ago

[HEALTH] 2 sources
Novo Nordisk and Global Weight‑Loss Drug Advertising Restrictions
Most countries bar direct ads for prescription weight‑loss drugs like Novo Nordisk’s Ozempic and Wegovy; only the US and New Zealand permit such advertising due to free‑speech protections.
8 days ago

[BUSINESS] 40 sources
Novo Nordisk sues Eli Lilly over alleged false advertising of weight‑loss drugs
Novo Nordisk sued Eli Lilly in New Jersey, alleging its ads compare Lilly’s drugs to lower‑dose Wegovy/Ozempic and mislead consumers, seeking injunctions and damages amid a $100 bn GLP‑1 market fight.
9 days ago

[HEALTH] 2 sources
Semaglutide generic approvals boost access in Canada and South Africa
Health Canada approved Aspen's generic semaglutide while Novo Nordisk launched an authorised Ozempic copy in South Africa, both aimed at expanding access as patents expire and supply challenges linger.
10 days ago

[HEALTH] 2 sources
Novo Nordisk's oral Wegovy tablet tops 3 million US prescriptions and wins EU approval
Novo Nordisk’s oral Wegovy tablet logged over 3 million U.S. prescriptions in six months and secured EU approval for 27 members, expanding its market amid rising competition with Eli Lilly.
10 days ago

[HEALTH] 2 sources
Paraná Expands Free Glargina Insulin Access through Brazil’s SUS
Paraná’s SUS will extend free insulin glargina to all 22 health regions, replacing NPH with once‑daily dosing for seniors 70+ and children, aiming to treat up to 9,700 diabetics in Curitiba.
11 days ago

[HEALTH] 11 sources
Semaglutide and GLP-1 drugs show health benefits and risks globally
Studies link semaglutide and other GLP‑1 drugs to lower cancer and dementia risks, while noting rare eye side effects; generic versions appear in Canada, a new oral pill launches in the UK, and US GLP‑1 use for
11 days ago

[HEALTH] 8 sources
EU Approves First Oral GLP‑1 Weight‑Loss Pill, Wegovy Tablet
The EU has approved Wegovy oral semaglutide, the first GLP‑1 weight‑loss tablet, based on trials showing ~13‑17% weight loss; launch slated for Q3 2026, while food firms like Nestlé adapt products for GLP‑1‑twe
12 days ago

[HEALTH] 2 sources
India Approves Novo Nordisk's Wegovy for Fatty Liver Disease Treatment
India's CDSCO approved Novo Nordisk's Wegovy injection for treating metabolic dysfunction‑associated steatohepatitis (MASH), marking the first GLP‑1 drug approved for this condition in the country.
12 days ago

[HEALTH] 5 sources
Brazilian Consumers Face Up to 25‑Fold Drug Price Gaps
Brazil's drug market shows stark price gaps, with a study revealing up to 25‑fold differences across pharmacies and a new semaglutide pen price cut aiming to improve access.
13 days ago

[HEALTH] 2 sources
Greek Health Minister Georgiadis to fund free obesity drugs
Greek Health Minister Georgiadis will fund free adult obesity drugs from the state budget after EU funds ran out, with a solution expected within 15 days to cover ~43,500 beneficiaries.
13 days ago

[HEALTH] 24 sources
Novo Nordisk's Wegovy oral tablet receives EU approval
EU regulators approve Novo Nordisk's Wegovy oral semaglutide tablet for obesity, showing ~17% weight loss and cardiovascular benefit; daily use with diet and exercise.
13 days ago

[HEALTH] 9 sources
Brazil expands access to modern diabetes drugs, including insulin glargina and Ozivy
Brazil's SUS is expanding insulin glargina distribution to children, adolescents and seniors, while EMS cuts Ozivy prices to R$10 a day, boosting access to modern diabetes treatments.
14 days ago

[HEALTH] 4 sources
Brazil defends 20‑year drug patent limit in health committee hearing
Brazil’s health committee hearing defended a 20‑year drug patent term, citing SUS cost savings and industry claims the limit is sufficient, while warning that extensions could cost up to R$ 16 bn.
14 days ago

[HEALTH] 4 sources
Medical AI and Semaglutide Implant Highlight Health Tech Advances in Brazil and Canada
A Brazil lecture will discuss AI and digital tools in medicine, while a Canadian firm develops a six‑month semaglutide implant to improve obesity and diabetes treatment adherence.
15 days ago

[HEALTH] 3 sources
Vivani Medical's NPM-139 semaglutide implant begins early human trials for obesity and type‑2 diabetes
Vivani Medical’s NPM-139 semaglutide implant, developed with Novo Nordisk, starts early human trials to deliver a year‑long obesity and type‑2 diabetes therapy, aiming to improve adherence over weekly injectors
15 days ago

[HEALTH] 4 sources
Obesity patients confront weight‑regain despite surgery and new therapies
Obesity is chronic; weight‑regain after bariatric surgery affects 20‑30% of patients, prompting combined endoscopic and GLP‑1 treatments with ongoing multidisciplinary care.
17 days ago

[HEALTH] 4 sources
Greek obesity expert says stopping treatment causes weight regain
Greek endocrinologist warns stopping obesity treatment leads to weight regain and urges continued therapy despite funding concerns.
17 days ago

[HEALTH] 3 sources
Wegovy weight‑loss drug shows stronger safety signal for rare vision loss as UK rolls out oral pill
Study of FDA data finds Wegovy has a five‑fold stronger safety signal for rare vision‑loss condition NAION, while the UK launches a daily oral Wegovy pill with strict dosing rules.
17 days ago

[HEALTH] 2 sources
Novo Nordisk launches Brazil digital pharmacy and brings Wegovy to Peru
Novo Nordisk opened Brazil’s NovoCare Farmácia digital pharmacy for Ozempic, Wegovy and Rybelsus, and launched Wegovy in Peru with its Vive Ligero campaign, expanding obesity and diabetes treatment access in L
17 days ago

[HEALTH] 2 sources
Novo Nordisk to assess Vivani's year‑long semaglutide implant for obesity maintenance
Novo Nordisk will evaluate Vivani Medical's NPM‑139 semaglutide implant, a year‑long device intended to improve obesity treatment adherence, with a Phase 1 trial slated for mid‑2026.
19 days ago

[HEALTH] 2 sources
China adds semaglutide to essential drug list, expanding diabetes care
China will list semaglutide on its essential drug list from Sept 1, boosting nationwide diabetes treatment access and opening the market to generics.
20 days ago

[BUSINESS] 2 sources
Novo Nordisk launches new Wegovy variant in Singapore amid obesity‑drug competition
Novo Nordisk has introduced a 7.2 mg Wegovy formulation in Singapore, aiming to keep its first‑mover edge in the obesity market as competition from Eli Lilly intensifies and overall sales pressure grows.
22 days ago

[HEALTH] 6 sources
Semaglutide weight‑loss drugs face safety warnings amid misuse concerns
Health officials across South Africa, Argentina, Chile, the US and Mexico warn that rising off‑label use of semaglutide for weight loss brings safety risks, urging medical supervision and regulated supply.
23 days ago

[HEALTH] 13 sources
UK launches oral Wegovy weight‑loss pill, pricing similar to injection
The oral Wegovy weight‑loss pill launched in the UK, priced £98‑£200/month, offering a needle‑free alternative and drawing strong consumer interest.
27 days ago

[HEALTH] 3 sources
Germany’s surge in GLP‑1 weight‑loss drugs and pending oral semaglutide approval
Germany’s use of GL‑1 weight‑loss injectables surges, prompting warnings over illegal prescriptions, while an oral semaglutide pill awaits EU approval after U.S. clearance.
27 days ago

[HEALTH] 2 sources
Brazil's Eurofarma‑Novo Nordisk program slashes obesity pen prices
Eurofarma and Novo Nordisk's EuroCuida program cuts Brazil's Poviztra and Extensior pen prices, while the Reciclaneta recycling scheme reaches 100 collection points and 120k pens.
28 days ago

[HEALTH] 2 sources
US Medicare launches GLP-1 Bridge program for weight‑loss drugs
Medicare’s new GLP‑1 Bridge pilot lets eligible seniors access weight‑loss drugs like Wegovy for $50 a month, aiming to curb obesity‑related health costs.
28 days ago

[HEALTH] 2 sources
Brazil details drug approval process and biosafety lab standards
Brazil outlines a decade‑long drug approval path involving Anvisa reviews and SUS inclusion, and details its four‑tier biosafety lab classification (NB1‑NB4) with strict containment for high‑risk agents.
29 days ago

[HEALTH] 4 sources
Health Canada authorizes first generic semaglutide injection for weight loss
Health Canada approved Apotex's generic semaglutide injection Svemia for weight loss in people 12+, the first such product, joining two diabetes generics and with six more submissions under review.
about 1 month ago

[HEALTH] 2 sources
Novo Nordisk Medicare Coverage Expands Wegovy to 3.8 Million US Seniors
Medicare will cover Novo Nordisk’s obesity drug Wegovy for up to 3.8 million seniors from July 2026 with a $50 copay, but most beneficiaries are unaware of the new Bridge program.
about 1 month ago

[HEALTH] 2 sources
Brazil's SUS Begins Semaglutide Trial and Opens First Smart ICU
Brazil's SUS starts a semaglutide trial for severe obesity and opens its first AI‑driven smart ICU, marking major health‑system innovations.
about 1 month ago

[HEALTH] 2 sources
Brazil's SUS drug access challenged by court delays and new obesity medication study
Brazil finds most court‑sought drugs already approved for SUS yet delayed, while a new study tests semaglutide for obesity to inform possible public‑health inclusion.
about 1 month ago

[HEALTH] 2 sources
Brazil's Health Ministry Launches Semaglutide Pilot for Obesity Treatment in SUS
Brazil's health ministry started a two‑year semaglutide pilot in SUS, enrolling 250 obese patients at a Rio Grande do Sul hospital to assess weight loss, quality of life and costs; the drug is not yet publicly‑
about 1 month ago

[HEALTH] 2 sources
Novo Nordisk introduces new obesity treatments in the Dominican Republic
Novo Nordisk launches Wegovy injectable and an oral semaglutide pill in the Dominican Republic, targeting a population where 68% are overweight and promoting a support programme for obesity treatment.
about 1 month ago

[HEALTH] 2 sources
Greece faces two‑month drug shortage for obesity patients
Around 71,000 Greeks on the Recovery Fund’s obesity drug programme face a two‑month gap when it ends June 30, leaving them without Mounjaro or Wegovy until national funding begins on Sept 1, risking weight‑reg
about 1 month ago

[HEALTH] 13 sources
Brazil's Health Ministry launches semaglutide pilot for obesity treatment in SUS
Brazil’s Health Ministry launched a two‑year SUS pilot in Rio Grande do Sul, giving semaglutide to 250 severe‑obesity patients to evaluate weight loss, health outcomes and cost for possible public use.
about 1 month ago

[HEALTH] 3 sources
Eli Lilly's experimental weight‑loss drug retatrutide shows major weight loss in trials
Eli Lilly's experimental drug retatrutide, a triple‑hormone agonist, caused up to 24 % body‑weight loss in Phase 3 trials but is not FDA‑approved, with mild GI side effects and FDA cautions.
about 1 month ago

[HEALTH] 3 sources
Novo Nordisk proposes 59% discount for semaglutide in Brazil's SUS
Novo Nordisk has offered a 59% discount on semaglutide to introduce the obesity drug into Brazil's public health system for high‑risk patients, after a previous costly proposal was rejected.
about 1 month ago

[BUSINESS] 7 sources
Eli Lilly plans European launch of obesity pill, U.S. MFN pricing may shape rollout
Eli Lilly will launch its obesity drug Orforglipron in Europe/UK in late 2026, focusing on telehealth and public reimbursement, while U.S. MFN pricing policy may affect pricing. A phase‑3 trial showed 28 % avg.
about 1 month ago

[HEALTH] 2 sources
US patients face insurance cuts to GLP-1 weight‑loss drugs
US insurers are dropping coverage for GLP‑1 weight‑loss drugs like Zepbound and Wegovy, affecting millions; patients can appeal by documenting qualifying health conditions and using prior authorizations.
about 1 month ago

[HEALTH] 8 sources
Brazil's Health Ministry to Study GLP‑1 Weight‑Loss Drugs for SUS
Brazil's health ministry will test GLP‑1 weight‑loss drugs in 250 super‑obese patients to assess clinical and economic benefits for SUS, while encouraging local production to cut prices.
about 1 month ago

[HEALTH] 2 sources
UK approves first daily oral GLP-1 weight-loss pill
UK’s MHRA approved Novo Nordisk’s daily oral semaglutide pill, the first GLP‑1 tablet for obesity, pending private‑market launch and not yet NHS‑covered.
about 1 month ago

[HEALTH] 5 sources
Eurofarma slashes Brazil obesity and diabetes pen prices by up to 48%
Eurofarma announced up to 48% cuts on its semaglutide pens Poviztra (obesity) and Extensior (diabetes) in Brazil, with 1 mg doses falling to R$309 and other doses receiving 40‑46% discounts under its EuroCuida
about 1 month ago

[BUSINESS] 2 sources
Eli Lilly accelerates acquisitions as weight‑loss drug Retatrutide cuts weight by 28%
Eli Lilly announced 13 acquisitions in 2026 and reported Retatrutide’s phase‑3 trial cut participants’ weight by 28.3% (70 lb). Q1 sales rose 55.5% to $19.8 bn while German investment was cut.
about 1 month ago

[HEALTH] 2 sources
GLP-1 obesity drugs in focus as Medicare pilot launches and Swiss biotech research emerges
Medicare will roll out a $50‑per‑month GLP‑1 weight‑loss pilot in the US, while Swiss biotech MetaShape reports early data that its MS 001 may boost GLP‑1 effectiveness by sparing muscle and increasing fat burn
about 1 month ago

[HEALTH] 2 sources
Anvisa clears Cristália's semaglutide weight‑loss pen produced in China
Anvisa approved Cristália’s semaglutide weight‑loss pen, to be made in China with plans for Brazilian market debut in 2026 and local production transfer by 2028.
about 1 month ago

[HEALTH] 2 sources
ADA 2026 conference reports breakthrough combo drug CagriSema for type‑2 diabetes
ADA 2026 in New Orleans unveiled CagriSema, a cagrilintide‑semaglutide combo that cut HbA1c and delivered up to 14 % weight loss, while confirming semaglutide is a synthetic GLP‑1 drug used for diabetes and ob‑
about 1 month ago

[HEALTH] 4 sources
Brazil's EMS launches Ozivy, first domestically produced semaglutide pen
EMS launches Ozivy, Brazil's first semaglutide pen for type 2 diabetes, priced at R$452 (R$287 with discount) after ANVISA approval; 500 k units released nationwide.
about 1 month ago

[HEALTH] 3 sources
France begins reimbursing Wegovy and Mounjaro anti‑obesity treatments
France starts reimbursing 65 % of Wegovy and Mounjaro for eligible obese patients, limiting prescriptions to specialized centers and projecting €100 million in annual costs.
about 1 month ago

[HEALTH] 6 sources
France to reimburse Wegovy and Mounjaro for obesity treatment starting Monday
France will reimburse 65% of Wegovy and Mounjaro for eligible obesity patients from Monday, covering up to one million people and costing an estimated €100 million by 2027.
about 2 months ago

[HEALTH] 3 sources
Brazil's Hospital da Criança de Brasília adopts liraglutide for adolescent obesity treatment
HCB in Brazil uses liraglutide, a Ministry‑approved GLP‑1 drug, to treat adolescent obesity alongside nutrition, psychology and other specialties.
about 2 months ago

[HEALTH] 2 sources
UK approves first oral GLP‑1 weight‑loss pill, prompting massive consumer interest
The UK’s MHRA has approved oral semaglutide, the first tablet GLP‑1 weight‑loss drug, sparking over 70,000 sign‑ups; the £99‑a‑month pill offers ~14% weight loss in 64 weeks and awaits NHS approval.
about 2 months ago

[BUSINESS] 2 sources
Novo Nordisk opens Czech obesity‑drug plant in Bohumil
Novo Nordisk opened a 300‑person plant in Bohumil, Czech Republic, investing over 8 bn CZK to produce obesity and diabetes medicines for local use and export, marking a strategic boost to Czech pharma self‑suff
about 2 months ago

[HEALTH] 2 sources
Semaglutide combinations and oral form improve blood sugar and weight in new studies
New studies find weekly cagrilintide‑semaglutide injections and oral semaglutide both lower HbA1c, aid weight loss, and improve metabolic markers in type 2 diabetes patients.
about 2 months ago

[HEALTH] 3 sources
UK Approves First Oral GLP-1 Weight‑Loss Pill
The UK’s MHRA approved semaglutide (Wegovy) tablets—the first oral GLP‑1 weight‑loss pill—available privately for adults with obesity, pending NHS review.
about 2 months ago

[HEALTH] 3 sources
UK regulator approves Wegovy weight‑loss tablet for private prescription
The UK MHRA has approved Wegovy's oral semaglutide tablet for private prescription, targeting adults with obesity (BMI ≥ 30 or 27‑30 with a health condition). It is not yet NHS‑covered and is expected to spur a
about 2 months ago

[HEALTH] 2 sources
UK approves Novo Nordisk's Wegovy oral weight‑loss tablet
UK regulators approved Novo Nordisk's Wegovy oral tablet, the first in Europe, for private prescription to treat obesity; NHS rollout pending NICE approval.
about 2 months ago

[HEALTH] 2 sources
Experimental drug survodutida cuts liver fat by up to 70% in phase‑3 trial
Phase‑3 trial of survodutida in the US and Spain shows up to 70% liver‑fat reduction and cardiovascular benefits in obese patients, though longer studies are needed.
about 2 months ago

[HEALTH] 2 sources
France to reimburse anti‑obesity drugs as Italy urges comparable access
France will start reimbursing tirzepatide and semaglutide for severe obesity on 15 June, prompting Italy’s obesity society to call for a similar, sustainable access plan under Law 149/2025.
about 2 months ago

[BUSINESS] 2 sources
Brazil sees new semaglutide pen launch and upbeat Pague Menos stock outlook
Ávita Care aims to launch a new semaglutide weight‑loss pen in Brazil by June, while Safra Bank lowers Pague Menos' price target but predicts a 66% share rise.
about 2 months ago

[HEALTH] 2 sources
HK inno.’s ecnoglutide outperforms semaglutide in obesity trial
HK inno.’s obesity drug ecnoglutide cut weight 35% more than semaglutide in a 20‑week phase‑2 trial of 163 Chinese patients, with twice as many achieving ≥10% loss and better tolerability.
about 2 months ago

[BUSINESS] 2 sources
Novo Nordisk pursues longevity and aesthetic medicine as it diversifies beyond obesity drugs
Novo Nordisk seeks to broaden its portfolio into longevity and aesthetic medicine after its stock fell, highlighting semaglutide’s potential organ‑protective effects beyond weight loss.
about 2 months ago

[HEALTH] 2 sources
Eli Lilly's experimental weight‑loss drug retatrutide shows strong trial results, fuels US demand despite lack of FDA OK
Eli Lilly’s experimental GLP‑1 drug retatrutide posted up to 30% weight loss in Phase 3 trials, boosting its stock and sparking U.S. demand despite lacking FDA approval and raising safety concerns.
about 2 months ago

[HEALTH] 3 sources
Retatrutide injectable cuts weight and blood sugar in phase‑3 trial for type‑2 diabetes
Phase‑3 trial of retatrutide, a weekly triple‑hormone injectable, led by Harpreet S. Bajaj, reduced weight four‑fold and more than halved blood sugar in type‑2 diabetes patients across the US, Mexico and India.
about 2 months ago

[HEALTH] 2 sources
Ecnoglutide Shows Superior Weight Loss to Semaglutide in Chinese Clinical Trial
Ecnoglutide cut more weight than semaglutide in a Chinese trial, showing 35% greater loss and better waist reduction, while experts stress genetic factors cause varied responses to GLP‑1 drugs.
about 2 months ago

[HEALTH] 5 sources
Boehringer Ingelheim's Survodutide Shows Strong Weight‑Loss Results but Raises Tolerability Concerns
Survodutide achieved up to 16.6 % weight loss, 34 % visceral‑fat and 63 % liver‑fat reductions, but 19‑25 % of patients stopped treatment due to gastrointestinal side effects, sparking investor concerns.
about 2 months ago

[HEALTH] 5 sources
Eli Lilly's Retatrutide Shows Up to 28% Weight Loss in Clinical Trials
Eli Lilly's experimental drug retatrutide cut weight up to 28% and improved diabetes markers in phase‑3 trials, but remains unapproved amid illegal sales in Brazil.
about 2 months ago

[HEALTH] 2 sources
Pfizer and Novo Nordisk present new obesity drug data at ADA conference
Pfizer unveiled data on its experimental monthly obesity injection berobenatide, showing similar side‑effects to Wegovy and up to 15% weight loss, while Novo Nordisk’s CEO highlighted semaglutide’s potentialfor
about 2 months ago

[HEALTH] 3 sources
American Diabetes Association Conference Highlights Monthly‑Dosing Diabetes and Obesity Drugs
ADA's June 2026 meeting presented data on monthly‑dosing triple‑G diabetes drugs and rising competition among obesity‑treatment makers, highlighting safety, clinical gaps and broader health implications.
about 2 months ago

[HEALTH] 4 sources
Eli Lilly's retatrutide cuts obesity, sleep apnea and knee pain in Phase 3 trials
Eli Lilly's retatrutide Phase 3 trials show up to 28% weight loss, 60% reduction in sleep‑apnea severity, and major knee‑pain relief, plus A1C drops for type 2 diabetes.
about 2 months ago

[BUSINESS] 2 sources
Novo Nordisk opens Czech plant for diabetes and obesity drugs
Novo Nordisk is opening a multi‑billion‑crown plant in Jevany, Czech Republic, to make ingredients for new diabetes and obesity drugs, amid a booming global market.
about 2 months ago

[HEALTH] 2 sources
Novo Nordisk promotes obesity awareness at Greece's BeWell Festival
Novo Nordisk and IMEROESA highlighted obesity prevention at Athens' BeWell Festival (June 6‑7), offering BMI checks, counseling, and a panel to shift the narrative on weight management.
about 2 months ago

[HEALTH] 2 sources
Novo Nordisk launches Wegovy oral weight‑loss pill in the UAE
Novo Nordisk has launched the oral Wegovy weight‑loss pill in the UAE, the first market outside the US, targeting the country’s high obesity rates with a drug shown to cut weight by 17 percent on average.
about 2 months ago

[HEALTH] 2 sources
Cigna to End GLP‑1 Weight‑Loss Drug Coverage for Employees
Cigna will stop covering GLP‑1 obesity drugs such as Wegovy and Zepbound for its employee health plan on July 1, 2026, citing cost concerns while maintaining coverage for diabetes use and older weight‑loss meds
about 2 months ago

[HEALTH] 6 sources
Brazil's EMS launches first domestic semaglutide weight‑loss pen Ozivy
EMS launches Brazil's first domestic semaglutide pen Ozivy on 15 June, priced at R$ 452 per unit with a three‑month starter pack at R$ 863.23, aiming to cut obesity‑drug costs by about 30 %.
about 2 months ago

[BUSINESS] 2 sources
Eli Lilly broadens collaborations on obesity treatments with Camurus and CVS Caremark
Eli Lilly secured a global partnership with Camurus for its obesity drug technology and a U.S. reimbursement deal with CVS Caremark for GLP‑1 medicines, expanding access to up to 90 million patients.
about 2 months ago

[HEALTH] 3 sources
France to reimburse obesity drugs Wegovy and Mounjaro
France will start reimbursing the GLP‑1 obesity drugs Wegovy and Mounjaro from mid‑June 2026 at 65% (effectively up to 100% for most), covering about a million patients and costing roughly €100 million a year.
2 months ago

[HEALTH] 141 sources
GLP‑1 Drugs Drive New Treatments, Coverage Plans and Safety Scrutiny
GLP‑1 drugs show promise for addiction treatment, gain Medicare coverage, face safety scrutiny over rare vision loss, spark aesthetic demand, and reduce obesity‑related disease risk in large U.S. studies.
2 months ago

[HEALTH] 13 sources
France to reimburse Wegovy and Mounjaro obesity drugs
France will become the EU’s first country to reimburse GLP‑1 obesity drugs Wegovy and Mounjaro for severe obesity, covering up to 100% of costs under strict eligibility from mid‑June, at an estimated €100 m a‑n
2 months ago

[HEALTH] 2 sources
Novo Nordisk's oral Wegovy pill cleared by EU regulators
EU regulators gave a positive opinion on Novo Nordisk's oral Wegovy tablet, the first GLP‑1 obesity drug in pill form, showing 16.6 % average weight loss in trials and awaiting final EU approval.
2 months ago

[HEALTH] 4 sources
Eli Lilly's obesity drug retatrutide shows over 28% weight loss in trial
Eli Lilly's experimental obesity drug retatrutide cut participants' weight by an average of 28% in a phase‑3 trial, with over 45% losing at least 30%, and a reduced rate of dysesthesia side effects, paving the
2 months ago

[HEALTH] 2 sources
Quirónsalud hosts integrated obesity treatment conference in Sevilla
Quirónsalud hospitals in Sevilla hold a free May 25 conference on integrated obesity treatment with Lilly and Novo Nordisk.
2 months ago

[BUSINESS] 2 sources
BioNxt Solutions moves semaglutide oral film into active development with Germany’s Gen‑Plus
BioNxt Solutions and Germany’s Gen‑Plus begin active development of a sublingual semaglutide oral film for GLP‑1 therapies.
2 months ago

[BUSINESS] 2 sources
Hims & Hers CEO and CFO sell shares amid sharp earnings miss
CEO sold 436k shares and CFO sold 7.9k shares of Hims & Hers as the company posted a massive Q1 earnings miss.
3 months ago

[HEALTH] 2 sources
Novo Nordisk reports up to 28% weight loss with high‑dose Wegovy in trial
Novo Nordisk shows high‑dose Wegovy can cut weight by ~28%, while CagriSema achieves 22.7% loss.
3 months ago

[BUSINESS] 2 sources
Novo Nordisk's Wegovy deal pulls Hims & Hers shares down 15%
Hims & Hers stock fell 15% after a Q1 loss, despite a new Wegovy partnership with Novo Nordisk.
3 months ago

[BUSINESS] 4 sources
Novo Nordisk shares rise modestly in early May
Novo Nordisk stock climbs from €30 to about €40, up 0.7% on May 11.

Sources

100percentfedup.com · 247wallst · 98fmnatal.com.br · absolutegeeks.com · ac24horas.com · acapa.com.br · ad-hoc-news · adtv.ig.com.br · aeiou.pt · aerzteblatt.de · agazetarm.com.br · ageas.com · aktiencheck · aktienkurs-orderbuch.finanznachrichten.de · alagoas24horas.com.br · allurantmedical.com · americanbankingnews · amodireito.com.br · amp.bemparana.com.br · anoticiaregional.com.br · aquiacontece.com.br · aquiagora.net · archive.in.gr · archynewsy.com · atarde.com.br · athleticsasia.org · atibaia.com.br · atualidadepolitica.com.br · avronline.de · azsalute.it · babadosebadalos.com.br · bamleik.no · barlettanews.it · bemparana.com.br · bettinginsider.com · beverlyhillsplasticsurgeryinc.com · bienpublic.com · bizcommunity.com · blogdomagno.com.br · blogs.ne10.uol.com.br · bp22.bemparana.com.br · br.paipee.com · brandonsun.com · brasilemfolhas.com · bringyourownbaby.com.my · businessam.be · businesstoday.in · ca.sports.yahoo.com

This summary has been updated 1 time: see revision history